[A randomized controlled study of PSK combined immuno-chemotherapy for adenocarcinoma of the lung. The Advanced Lung Cancer Immuno-chemotherapy Study Group].
In a randomized controlled study of chemotherapy (CDDP 100 mg/m2 day 1, VDS 3 mg/m2 day 1, 8, 15) vs. immuno-chemotherapy combined with PSK 3 g/day for adenocarcinoma of the lung (stage III, IV, p. s. 0, 1, 2), response rate for 169 cases with completed extramural review was 14.2%. As for the response rates for 138 complete cases, the chemotherapy group showed 17.9%, and the immuno-chemotherapy group was 16.9%. MST were 330 days and 331 days, respectively. In stage III cases, the response rates were 11.1% in the chemotherapy group and 37.5% in the immuno-chemotherapy group (p = 0.046). MST were 457 days (65.3 weeks) and 576 days (82.3 weeks), respectively. In terms of survival curve, it was suggested that the immuno-chemotherapy group was superior to the chemotherapy group (logrank test p = 0.075), but in stage IV cases, there was nothing outstanding in the immunochemotherapy group.
Nishiwaki
Y
Y
National Matsudo Hospital, Dept. of Internal Med.
Furuse
K
K
Fukuoka
M
M
Ota
M
M
Niitani
H
H
Asakawa
M
M
Nakai
H
H
Sakai
S
S
Ogawa
N
N
D000230:Adenocarcinoma / Q000188:drug therapy*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011509:Proteoglycans / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D014751:Vindesine / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D011509:Proteoglycans; C010770:polysaccharide-K; D002945:Cisplatin; D014751:Vindesine